Monday November 23 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

STALLERGENES

Nil


Contact Details:
6, rue Alexis de Tocqueville
ANTONY
cedex
92183
France
Tel:(33) 1 55 59 20 00
Fax:(33) 1 55 59 21 68
Email:drh@stallergenes.fr
WWW:

www.stallergenes.fr/




Recent Publications by STALLERGENES:

Molecular variability of group 1 and 5 grass pollen allergens between Pooideae species: implications for immunotherapy.
Summary Background Differences between major allergens from distinct grass...
10th November, 2009
Stallergenes SA, 6 rue Alexis de Tocqueville, 92160 Antony, France. Clin Exp Allergy. 2009 Nov 5.
DOI Direct Link
Mapping of the lingual immune system reveals the presence of both regulatory and effector CD4 T cells.
Summary Background Sublingual immunotherapy (SLIT) is safe and reduces...
22nd August, 2009
Research and Development, Stallergenes SA, Antony, France. Clin Exp Allergy. 2009 Aug 20.
DOI Direct Link
Development of an allergen extract for sublingual immunotherapy - evaluation of Staloral.
Background: Specific immunotherapy (IT) is an effective treatment for...
16th July, 2009
Scientific and Medical Department, Stallergenes Italia, Milan, Italy. Expert Opin Biol Ther. 2009 Sep;9(9):1207-15.
DOI Direct Link
Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route.
BACKGROUND: Sublingual immunotherapy (SLIT) has been established in humans...
23rd June, 2009
Research and Development, Stallergenes SA, Antony, Cedex, France. Clin Exp Allergy. 2008 Nov;38(11):1819-29. Epub 2008 Jul 17.
DOI Direct Link
Human dendritic cells stimulated via TLR7 and/or TLR8 induce the sequential production of Il-10, IFN-gamma, and IL-17A by naive CD4+ T cells.
Depending upon which TLRs are triggered, dendritic cells (DCs) may orient...
9th May, 2009
Research and Development, Stallergenes SA, France. J Immunol. 2009 Mar 15;182(6):3372-9.
DOI Direct Link

View more STALLERGENES research publications.

Press Releases on STALLERGENES:

BioPortfolio Logo
STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial 16th September, 2009 Stallergenes
ANTONY, France, September 16 /PRNewswire-FirstCall/ -- Stallergenes S.A. has announced the first results of a new phase IIb/III clinical trial (VO59.08) conducted in allergic rhinitis caused by
Stallergenes : Investor Meeting: Webcast is Available 25th March, 2009
PARIS, March 25 /PRNewswire/ -- Hello, The investor meeting relating to the 2008 earnings and 2009 outlook has been webcasted. The presentation is available in English from the following link:
STALLERGENES: 2008: Strong Performance 24th March, 2009
ANTONY, France, March 24 /PRNewswire/ -- The Board of Directors, meeting on 23 March 2009 under the chairmanship of Albert SAPORTA, approved the 2008 consolidated financial statements: EUR
Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS* 24th March, 2009
ANTONY, France, March 24 /PRNewswire/ -- Stallergenes S.A. and Solvay Pharmaceuticals Marketing and Licensing AG (subsidiary of Solvay Group) announce the signing of an exclusive partnership agreement
Stallergenes Inaugurates the Biggest Pharmaceutical Allergen Production Unit in the World 10th September, 2008
ANTONY, France, September 10 /PRNewswire/ -- Stallergenes S.A. officially inaugurates its new pharmaceutical production unit, located in the Paris area. Designed to comply with the most

BioNews Results for STALLERGENES:

Stallergenes, S.A. (GENP.PA) Continued Dynamic Growth / Cumulative Sales to the end of September 2009 up 12%
BioSpace:  Oct 16 2009 6:48PM Matching: stallergenes
STALLERGENES: Continued Dynamic Growth / Cumulative Sales to the end of September 2009 up 12%
Montana's News Station:  Oct 16 2009 6:25AM Matching: stallergenes
STALLERGENES: Continued Dynamic Growth / Cumulative Sales to the end of September 2009 up 12%
TickerTech.com:  Oct 16 2009 3:49AM Matching: stallergenes
STALLERGENES: Continued Dynamic Growth / Cumulative Sales to the end of September 2009 up 12%
NewsBlaze:  Oct 15 2009 7:25PM Matching: stallergenes
STALLERGENES: Continued Dynamic Growth / Cumulative Sales to the end of September 2009 up 12%
Pharma Live:  Oct 15 2009 8:38PM Matching: stallergenes
Promote your company here: BioNewsCast - Press Release Distribution

View more STALLERGENES news.

STALLERGENES Patents:

US Patent No.Title
7285650 Cloning and sequencing of the allergen Dac g5 of Dactylis glomerata pollen, its preparation and its use
5290563 Method for combining a mixture of heterogeneous substances with liposomes

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 551 times since April 2007, the link to the organisation's website has been followed 55 times

Recent Search Terms used to find this page: DRH stallergenes | stallergenes france | stallergenes.fr address | stallergenes email contact person | DRH stallergenes | stallergenes.fr | Stallergenes France | STALLERGENES france contact | stallergenes | stallergenes | .

Search for more companies in ANTONY

Search for more companies in cedex



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for STALLERGENES

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.